Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
Study sponsor: Aytu BioPharma, Inc. · AYTU
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-06Estimated
Enrollment · participants260Estimated
Source updated2024-03-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.